Clinical Trial Update: UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating UCN-01 in combination with topotecan in patients with recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Topotecan (topotecan)
• UCN-01 (7-hydroxystaurosporine)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Fallopian Tube Cancer, Ovarian Cancer | Phase 1 | Status: COMPLETED